Risedronate for treatment of osteoporosis
Hagino, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 67(5): 948-953
2009
ISSN/ISBN: 0047-1852 PMID: 19432115 Document Number: 628558
Risedronate is effective and approved for the treatment of osteoporosis in Japan. Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts. Risedronate was shown to significantly decrease the risk of nonvertebral fractures including hip fractures as well as vertebral fractures in placebo-controlled, 3-year clinical trials in postmenopausal women with osteoporosis. The efficacy of risedronate elucidated by recent clinical studies was reviewed.